Cambridge Cognition Holdings PLC - Cambridge, England-based brain health software - Expands partnership with Actinogen Medical Ltd for phase 2b/3 XanaMIA Alzheimer’s trial. Says Actinogen will continue to utilise Cambridge Cognition’s full product suite, leveraging its tools for more precise clinical measurements. Notes that the trial includes 220 patients experiencing Alzheimer’s induced dementia, with patients receiving a placebo or emestedastat once daily. The trial intends to show its ability to slow Alzheimer’s progression through assessing various endpoints over 36 weeks. Says the ongoing use of Cambridge Cognition’s full product suite ensures greater comparability and superior data quality across Actinogen’s clinical development programme.
Cambridge Cognition Chief Operating Officer Rob Baker says: ‘This partnership highlights the value of our integrated platform in advancing innovative studies. By leveraging our comprehensive suite of solutions, sponsors can optimise their clinical assessments while upholding exceptional data quality standards. Our approach ensures consistent, reliable endpoint measurements across the entire trial, ultimately strengthening the scientific validity of research outcomes.’
Current stock price: 42.50 pence, closed up 6.3% on Thursday in London
12-month change: down 14%
Copyright 2025 Alliance News Ltd. All Rights Reserved.
